A moderate negative correlation was observed between IL-21 and IL-22 serum levels in patients with benign breast lesions (rS = −0.663, p = 0.002), whereas no such correlation was found in patients diagnosed with breast cancer (rS = −0.109, p = 0.410). This evidence concerns the gene IL22 and breast carcinoma.